anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Guillain-Barre Syndrome (GBS) is the most prevalent acute peripheral polyneuropathy disorder. The disparities between populations and variations in the major risk factors highlight the importance of country-specific studies. This study aimed to report clinical characteristics and outcomes of ICU-admitted patients with GBS in an academic medical center in Iran.
METHODS: The data were collected retrospectively from all patients with GBS admitted to Namazi Hospital, affiliated with Shiraz University of Medical Sciences, (Shiraz, Iran), between March 2016 to March 2021. Specialized neurological information and the Acute Physiology and Chronic Health Evaluation (APACHE II) score were recorded. The SPSS software was used to analyze the data. The analyzed data were reported as numbers and percentages, or mean±SD, or median(Interquartile).
RESULTS: The study included 132 GBS patients, with an average age of 47.87±15.4 years and a male-to-female ratio of 1.69:1. More than half of the patients (58.5%) were classified as having an axonal disease. In patients with axonal illness, 51.4% of patients had lower limb powers<3, while only 36% of those had the demyelinating disease. This group also required mechanical ventilation more frequently (54% vs. 46%) and for a longer duration (26 [9-37] vs. 10 [1-61]) days. Pneumonia and sepsis were each observed in 16% of patients, and 12% developed a urinary tract infection. The most common type of GBS was acute inflammatory demyelinating polyneuropathy (AIDP). Only 6 (3.8%) patients died.
CONCLUSION: The axonal type of GBS was more frequent, and these patients required mechanical ventilation more frequently and for a longer duration than those in other electrophysiological categories. A preprint version of the manuscript is available at DOI: https://doi.org/10.21203/rs.3.rs-2181605/v1.
Facioscapulohumeral muscular dystrophy (FSHD) is a common form of adult muscular dystrophy often resulting also in cardiorespiratory deconditioning and weakness of the lower limbs. Although previous studies examined outcomes of interventions aimed at improving either cardiorespiratory fitness or muscle strength, the potential benefits of a rehabilitation program targeting both remain unexplored. Thus, the aim of this study was to evaluate changes following participation in a rehabilitation program combining aerobic and strength exercises. We conducted a retrospective analysis of 10 subjects with FSHD who participated in our rehabilitation program during 2018 and 2019. Each of the 20 sessions consisted of aerobic training on a cycloergometer and a moderate lower limb strength exercises on an isokinetic machine in combination with conventional therapy. The primary outcomes were walking speed, aerobic performance and isokinetic strength of the knee extensors and flexors. The secondary outcomes were fatigue, insomnia. VO2max and walking speed increased significantly by 2.125 ml·kg-1·min-1 [95% confidence interval (CI): 0.75-3.62, P = 0.022] and 0.28 m/s (95% CI: 0.16-0.4, P = 0.002), respectively. The effect size was small for V02max (Hedge's g, 0.44; 95% CI: -0.5 to 1.37) and large for walking speed (Hedge's g, 0.99; 95% CI: 0.06-1.92). The knee flexor strength significantly increased at rehabilitation discharge (repeated measures analysis of variance P = 0.004). Positive changes in fatigue and insomnia were also observed. Our preliminary results provide evidence that a relatively short course of a comprehensive rehabilitation program targeting both cardiorespiratory fitness and knee muscle strength can be beneficial for people with FSHD, which warrants further prospective studies.
ABSTRACT Systems and methods encourage users to rotate injection sites and avoid lipodystrophy. Sleeves and/or lost-tooth gear dials and/or microswitches in or on injection pens or their caps, on vials, and on other portable devices manually adjust an indicator before or after an injection to show a current or next injection site in accordance with a site rotation plan. Injected medicine packaging and related printed indicia encourage site rotation. Optical devices employing optical mouse or projection technology help locate and/or distribute injection sites within a body area. A mobile phone app tracks injections and locations to select next injection site, and can use imaging to locate a target injection site and optionally diagnose lipodystrophic conditions and record them. Tactile and print media educational tools are presented to help users palpate and identify lipos in body areas having injection sites. Date Recue/Date Received 2020-11-09
FIELD: medicinal endocrinology, pharmacy. SUBSTANCE: invention relates to application of α-cyclodextrine by the novel designation, namely, for providing oral administration of peptide analogs of releasing-hormone of luteininzing hormone (LH-RH). Invention involves also data about pharmaceutical compositions comprising α-cyclodextrin or its derivatives and mentioned peptide analogs of LH-RH. Proposed agent provides elimination of endocrinological disorders in women. EFFECT: valuable medicinal properties of composition, expanded assortment of non-invasive agents. 34 cl, 7 dwg, 4 tbl, 3 ex
Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
Rationale: Several studies have shown that pioglitazone, at either 30 to 45 mg per day, is safe and effective in randomized, controlled trials (RCTs) of 6- to 24-month duration (Belfort et al, NEJM 2006; Aithal et al, Gastroenterology 2008; Sanyal et al, NEJM 2010; Cusi et al, Annals Int Med 2016; Bril et al, Diabetes Care 2019). However, pioglitazone has shown to also improve glucose and lipid metabolism at the lower dose of 15 mg per day in patients with type 2 diabetes (Aronoff et al, Diabetes Care 2000; Miyazaki et al, Diabetes Care 2002; Rosenstock et al, Int J Clin Pract. 2002; Rajagopalan et al, Diabetes Res Clin Pract 2015). However, the effect of pioglitazone at doses of 15 mg per day on liver histology in patients with steatohepatitis (NASH) has not been previously examined.

Study aim: To examine the safety and efficacy of "low-dose" (15 mg/day) pioglitazone compared to placebo (control) in patients with type 2 diabetes and NASH in a 72-week randomized controlled study design.

Description: This is a single center, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of pioglitazone in subjects that are 21 to 75 years of age, with nonalcoholic steatohepatitis (NASH) confirmed by liver biopsy and who have type 2 diabetes. Eligible subjects will be enrolled into two treatments arms: Pioglitazone 15 mg or placebo in a ratio 1:1. All subjects will be enrolled and followed at the our research center, the University of Florida NIH-sponsored Clinical Translational Science Institute. Upon study entry, patients will undergo a detailed medical history, physical exam, baseline routine laboratories, EKG, elastography (VCTE). Those who meet al inclusion/exclusion criteria will undergo further imaging by MRI and measurement of blood diagnostic panels hormones and biomarkers relevant to the disease state (steatohepatitis). A liver biopsy, if not done prior to study entry, will be performed. Patients that qualify (NASH with fibrosis F1-F3) will be randomized in a double-blind fashion to either pioglitazone or placebo. They will be followed during 10 scheduled visits after randomization for 72 weeks of treatment. Blood testing, imaging and a liver biopsy will be repeated as done at baseline. After completion of the study treatment period, subjects will be followed for an additional period of 4 weeks without study medication (week 76).
Motion artifacts are a pervasive challenge in EEG ambulatory monitoring, often obscuring critical neurological signals and impeding accurate seizure detection. In this study, we propose a new approach of outlier based grouping of two level Singular Spectrum Analysis (SSA) decomposition combined with Relative Total Variation (RTV) filter for the effective removal of motion-induced noise from ambulatory EEG data. A two-stage SSA method was employed to decompose single-channel EEG signal, which had been interfered with, into various fre quency bands. The affected sub-band signal was then subjected to an RTV filter to estimate the artifact signal. Subtracting this estimated artifact signal from the contaminated sub-band signal yielded the filtered sub-band signal. Subse quently, the filtered sub-band signal was reintegrated with the other decomposed components from noise-free bands, culminating in the generation of the ultimate denoised EEG signal. Based on the comprehensive set of simulation results, it can be deduced that the algorithm described in the paper outperforms existing methods. It demonstrates superior metrics evaluation in terms of ΔSNR,η,MAE, andPSNRwhen compared to these alternatives. Our framework sig- nificantly enhances the quality of EEG data by successfully eliminating motion artifacts while preserving crucial brainwave information. To evaluate the prac tical impact of this noise reduction technique, we assess its performance in the context of seizure detection. The results reveal a substantial improvement in the accuracy and reliability of seizure detection algorithms when applied to EEG data preprocessed with proposed method.
Patients undergo SBRT every other day or on consecutive days for up to 14 days. Patients may receive hormonal therapy at the discretion of the treating physician.
The present invention relates to a capsule for regeneration of heart valves, which belongs to the technical field of a medicine. The present invention is mainly used for changing the condition that a rheumatic valvular heart disease only can be treated by an operation method at present; when the present invention is used, the rheumatic valvular heart disease can be healed by the medicine. The capsule for regeneration of heart valves is composed of master regenerating capsules No. 1 and auxiliary synergistic regenerating capsules No. 2, wherein each master regenerating capsule No. 1 of the capsule for regeneration of heart valves is composed of Mongolian tart fruit, lucid ganoderma, dwarf lilyturf tuber, etc.; each auxiliary synergistic regenerating capsule No. 2 of the capsule for regeneration of heart valves is composed of gynostemma pentaphylla, aweto and milkvetch root. The master regenerating capsules No. 1 and the auxiliary synergistic regenerating capsules No. 2 of the capsule for regeneration of heart valves are mainly used for treating valvular incompetence of rheumatic heart diseases, and valvular stenosis of the rheumatic heart diseases.
Quinapril is deesterified to the principal metabolite, quinaprilat, which is aninhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzesthe conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril inhypertension appears to result primarily from the inhibition of circulating and tissue ACE activity,thereby reducing angiotensin II formation. Quinapril inhibits the elevation in blood pressure causedby intravenously administered angiotensin I, but has no effect on the pressor response toangiotensin II, norepinephrine or epinephrine. Angiotensin II also stimulates the secretion ofaldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid reabsorption.Reduced aldosterone secretion by quinapril may result in a small increase in serum potassium. Incontrolled hypertension trials, treatment with quinapril hydrochloride alone resulted in meanincreases in potassium of 0.07 mmol/L (see PRECAUTIONS). Removal of angiotensin II negativefeedback on renin secretion leads to increased plasma renin activity (PRA).

While the principal mechanism of antihypertensive effect is thought to be through the reninangiotensin-aldosterone system, quinapril exerts antihypertensive actions even in patients with lowrenin hypertension. Quinapril hydrochloride was an effective antihypertensive in all races studied,although it was somewhat less effective in blacks (usually a predominantly low renin group) than innonblacks. ACE is identical to kininase II, an enzyme that degrades bradykinin, a potent peptidevasodilator; whether increased levels of bradykinin playa role in the therapeutic effect of quinaprilremains to be elucidated.
Participants with positive genotype-1 HCV RNA received 48 weeks of treatment of PegIntron Pen plus ribavirin and 24 weeks of follow-up. Participants who were non-genotype-1 HCV RNA positive received 24 weeks of treatment of PegIntron Pen plus ribavirin and 24 weeks of follow-up. Participants were asked to complete a questionnaire to measure the satisfaction and the use of training materials of PegIntron pen using a 1-5 score system provided in the questionnaire. The questionnaire was completed once at first follow-up visit. Efficacy measurements for sustained viral response HCV RNA was collected at week-24 of treatment and at week-24 of follow-up in positive Non-genotype-1 HCV RNA participants. Efficacy measurements for sustained viral response HCV RNA was collected at week-24 and at week-48 of treatment, and at week-24 of follow-up, for positive Genotype-1 HCV RNA participants.
The invention discloses a composition for treating an inflammatory bowel disease and belongs to the field of medicines. The composition comprises ganoderma lucidum, salvia miltiorrhiza, ginsengs, poria cocos, vitamins C, E and A and beta-carotene. The ganoderma lucidum, the salvia miltiorrhiza, the ginsengs and the poria cocos have the effects of enhancing blood supply and oxygen supply for a human body. The vitamins C, E and A and the beta-carotene have the effects of inhibiting the oxygen free radical activity, removing oxygen free radicals and protecting human body cells. The composition provides nutrients, oxygen and raw materials for development, update and repair of goblet cells and composition of an intestinal tract surface mucous layer barrier by goblet cell secretory mucoprotein. The composition has the obvious effects of eliminating inflammation, repairing intestinal tissues and establishing the normal intestinal tract surface mucous layer barrier of the human body and is an effective formula for treatment of the inflammatory bowel disease.
INTRODUCTION: There is a misperception in society that individuals with visual impairment are asexual and cannot marry, have children, or take care of children. In addition, individuals with visual impairment face difficulties in many aspects of life due to accessibility issues. Although it is expected that visually impaired individuals experience difficulties when having children, very few studies have focused on understanding the challenges women with visual impairment face in the process of having children. The aim of this study was to identify the challenges faced by mothers with visual impairment from preconception through the postpartum period in Turkey.
METHODS: Semistructured interviews were conducted with a purposive sample of 17 mothers with visual impairment. Participants were from 28 to 38 years of age, and their youngest children were 2 years old or younger. Participants were asked about their experiences with the decision to have children, pregnancy, birth, and postpartum. Content analysis was used to analyze and present the data.
RESULTS: Participants had 1 to 3 children and a mean age of 32.4 years. Eleven themes were identified within 4 periods: preconception, pregnancy, birth, and postpartum. Themes related to the experience of the preconceptional period included concern about the decision to have a child and the social pressure on the decision to have a child. Themes related to the experience of pregnancy included inaccessible pregnancy tests, emotional reactions to pregnancy, dissatisfaction with health care providers, and unmet expectations. Themes related to labor and birth included mixed feelings about labor dissatisfaction with health care providers and unmet expectations. Themes related to the postpartum period included personal care, infant care, reaction of the social network, and unmet expectations.
DISCUSSION: The mothers with visual impairment faced many challenges in the process of becoming a parent. Mothers expressed the need for accessible health services from institutions and health professionals.
Nursing homes in the intervention group will receive the SmartJournal intervention. They will be provided with toolboxes including tablets with SmartJournal installed, antibacterial touchscreen wipes, flashlights for monthly oral inspections, instruction video, instruction book and SmartJournal information posters. They will also receive oral hygiene equipment packages including toothbrushes for permanent teeth and prosthetic devices, dental floss, interdental brushes, toothpaste and inspection mirrors. Training, follow-up and technical support for SmartJournal usage will be provided by project staff employed at the Oral Health Centre of Expertise Rogaland. The intervention will last for 12 weeks.
Characterize the effect of LIFU to the bilateral dorsal posterior insula (dPI) and dorsal anterior cingulate cortex (dACC)) on autonomic control. The dPI is a critical brain area involved in autonomic function, being a core recipient of ascending pain and autonomic function. Similarly, the dACC has been strongly implicated in autonomic control and works with the insula for autonomic processing. Inconveniently, these brain regions lie deep to the cortex, prohibiting access using conventional noninvasive methods like transcranial magnetic stimulation (TMS). LIFU can be focused at depth to reach the insula and ACC with high spatial precision. However, the effect of LIFU to the human dPI and dACC on autonomic control is unknown. To address this, the investigators will target the right dPI and the dACC to assess how LIFU to each of these areas affects autonomic responses and subjective report to the cold pressor task, a safe, reproducible autonomic challenge.
The present invention relates to a functional composition for alleviating atopic dermatitis, which uses eco-friendly natural ingredients. More preferably, the present invention relates to a functional composition for alleviating atopic dermatitis, which uses a mixture of natural crude juices to improve and treat skin diseases, including atopic dermatitis, while preventing side effects of agents for treating atopic dermatitis. The composition according to the present invention is obtained by the method comprising the steps of: generating crude juices by chopping Artemisia argyi Lev. et Vant, Morus alba L., chlorophyl, Lentinula edodes, ginseng, Ceramium kondoi Yendo and Ginkgo biloba individually at a temperature of 10C; generating juice by chopping Zanthoxylum piperitum at a temperature of 20C; dipping dry white radish obtained by cutting white radish into a size of 3 cm and drying the cut radish for 2 months in the sun and in the shade alternately, in water at 10C to extract amylase; and introducing each of the juices of Artemisia argyi Lev. et Vant, Morus alba L., chlorophyl, Lentinula edodes, ginseng, Ceramium kondoi Yendo, Ginkgo biloba and Zanthoxylum piperitum, and the amylase to a mixing container at a weight ratio of 1:1 and mixing them to obtain a concentrated mixture; warming the mixture to 20C without degradation of nutrients and checking the solidified state of the mixture after 24 hours, and further checking the solidified state after additional 6-12 hours. According to the present invention, the composition comprising a mixture of natural juices with amylase extracted from white radish dipped in water is less irritating and is abundant with nutrients favorable to the skin, thereby increasing an effect of treating atopic dermatitis.
It aims to study the diagnostic effect of procalcitonin (PCT) and red blood cell distribution width (RDW) in premature septicemia (PS), and to analyze the prognostic evaluation value of PCT and RDW in PS. Ninety eight septicemia premature infants (SPI) who visited the neonatal intensive care unit of our hospital from June 2019 to July 2021 were selected and met the criteria. Based on the patient's condition and the neonatal shock score, they were separated into a severe group (SG) and a mild group (MG). There were 43 children and 55 children in the 2 groups, respectively. According to the survival status of SPI after 3 days of treatment, they were divided into a death group and a SG. It detected and analyzed the peripheral venous blood of SPI before treatment (BT) and after treatment (AT), and observed the changes of PCT and RDW. The comparison of general data between severe and mild SPI and their mothers did not have statistical significance (P > .05). The PCT of the SG was higher than that of the MG BT, on the 1st day and the 3rd day AT; The PCT BT and AT in both groups ranged from high to low on the 1st day and the 3rd day AT and BT (P < .05). The RDW in the SG were higher than those in the MG, and the RDW BT and AT in both groups were the highest on the 1st day AT; The RDW BT in the MG was higher than on the 3rd day AT, while the RDW BT in the SG was lower than on the 3rd day AT (P < .05). The optimal cutoff values for PCT on the 1st and 3rd day AT were 40.594ng/ml and 64.854ng/ml, respectively, with sensitivity of 100.0% and 100.0%, and specificity of 73.2% and 87.1% (P < .05). The optimal cutoff values for RDW on the 1st and 3rd day AT were 16.649% and 18.449%, respectively, with sensitivity of 100.0% and 100.0%, and specificity of 68.5% and 91.8% (P < .05). Monitoring the changes in PCT and RDW can promote the early diagnosis of PS and their prognosis evaluation.
A tablet that rapidly disintegrates in aqueous solution includes a partially collapsed matrix network that has been vacuum-dried above the collapse temperature of the matrix. The matrix is preferably at least partially dried below the equilibrium freezing point of the matrix. Vacuum drying the tablet above its collapse temperature instead of freeze drying it below its collapse temperature provides a process for producing tablets with enhanced structural integrity, while rapidly disintegrating in normal amounts of saliva. The tablet preferably carries a drug, such as acetaminophen. The matrix network of the tablet preferably includes a gum, a carbohydrate and the drug. Especially preferred embodiments also include a flavoring, a sweetener and surfactant. The gum is preferably acacia, guar, xanthan, carrageenan or tragacanth gum. The carbohydrate is preferably mannitol, dextrose, sucrose, lactose, maltose, maltodextrin or corn syrup solids.
Embodiments herein relate to hearing assistance devices and related systems and methods for providing visual feedback to a subject undergoing physical therapy or vestibular movement training. In an embodiment, a method of providing physical or vestibular therapy to a subject is included. The method can include prompting the subject to move in a predetermined direction by a predetermined amount as part of a first predetermined movement. The method can further include tracking movement of the subject using a first IMU disposed in a fixed position relative to the subject's head. The method can further include generating feedback data by comparing the tracked movement of the subject against the predetermined direction and amount of the first predetermined movement. The method can further include generating a feedback image using the feedback data. Other embodiments are included herein.